APAC IPOs & Placements

Zhen Zhou, Toh

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

China Resources Pharmaceutical / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/22928" target="_blank" data-smartkarma-citation="entities:22928:1">CR Pharmaceutical Group (3220 HK)</a> plans to raise US$1,932mm - US$2,321m in its IPO through selling 1,774.6m primary shares.Our fellow insight provider, <a href="https://www.smartkarma.com/profiles/13" target="_blank" data-smartkarma-citation="accounts:13">Kemp Dolliver, CFA</a>, has covered CR Pharma extensively in <a href="https://www.smartkarma.com/insights/cr-pharma-listing-part-1" target="_blank" data-smartkarma-citation="insights:5268">CR Pharma Listing: Part 1</a>, <a href="https://www.smartkarma.com/insights/cr-pharma-listing-part-2" target="_blank" data-smartkarma-citation="insights:5268">CR Pharma Listing: Part 2</a> and <a href="https://www.smartkarma.com/insights/cr-pharma-listing-part-3" target="_blank" data-smartkarma-citation="insights:5268">CR Pharma Listing: Part 3</a>.In this insight, we will run the deal through our framework, value the company through sum of the parts, examine each of the three China listcos and check CR Pharma's valuation against peers.

CR Pharmaceutical Group (3220 HK) plans to raise US$1,932mm - US$2,321m in its IPO through selling 1,774.6m primary shares.Our fellow insight provider, Kemp Dolliver, CFA, has covered CR Pharma extensively in CR Pharma Listing: Part 1, CR Pharma Listing: Part 2 and CR Pharma Listing: Part 3.In this insight, we will run the deal through our framework, value the company through sum of the parts, examine each of the three China listcos and check CR Pharma's valuation against peers.

Shanghai Pharmaceuticals Holding (2607 HK)

CR Pharma IPO - Valuation Is Rich at the Top End